Efficacy of SF 68 in the Treatment of Acute Diarrhea a Placebo-Controlled Trial

Buydens, P.; Debeuckelaere, S.

doi:10.3109/00365529609051997

Cited by 76 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is remarkable that enterocin L50A is still active after oxidation at Met 24 but that (1), and Mongolian airag (3). Nevertheless, in some instances (1,3), the experimental masses obtained after the purification of these bacteriocins have differed from the theoretical ones (5,190 Da for enterocin L50A and 5,178 Da for enterocin L50B). We suspect that these discrepancies are due to chemical modifications at Met residues which are likely to complicate the identification of enterocins.…”

Section: Discussionmentioning

confidence: 94%

“…Enterococci are an essential part of the endogenous gut microbiota of humans and animals, where they are believed to play a key role in the balance of the microbiota, thereby showing great potential as probiotics (2,5). They are also widespread in nature, found in wastewaters, feces, and slurry, as well as in soil and on plants (27), and are thus considered to be indicators for fecal contamination.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Production of Enterocins L50A, L50B, and IT, a New Enterocin, by Enterococcus faecium IT62, a Strain Isolated from Italian Ryegrass in Japan

Izquierdo

Bednarczyk

Schaeffer

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Enterococcus faecium IT62, isolated from ryegrass in Japan, was shown to produce three different bacteriocins, two of which had molecular masses and amino acid sequences that corresponded to those of enterocin L50A and enterocin L50B. These peptides existed, however, as chemically modified forms that were either N formylated or N formylated and oxidized at Met 24 . The third bacteriocin, named enterocin IT, had a molecular mass of 6,390 Da, was made up of 54 amino acids, and did not correspond to any known bacteriocin. However, enterocin IT was identical to the C-terminal part of the 16-amino-acid-longer bacteriocin 32 (T. Inoue, H. Tomita, and Y. Ike, Antimicrob. Agents Chemother., 50:1202-1212, 2006). For the first time, the antimicrobial activity spectra for enterocins L50A and L50B were determined separately and included a wide range of gram-positive bacteria but also a few gram-negative strains that were weakly sensitive. Slight differences in the activities of enterocins L50A and L50B were observed, as gram-positive bacteria showed an overall higher level of sensitivity to L50A than to L50B, as opposed to gram-negative ones. Conversely, enterocin IT showed a very narrow antimicrobial spectrum that was limited to E. faecium strains, one strain of Bacillus subtilis, and one strain of Lactococcus lactis. This study showed that E. faecium IT62, a grass-borne strain, produces bacteriocins with very different activity features and structures that may be found in strains associated with food or those of clinical origin, which demonstrates that a particular enterocin structure may be widespread and not related to the producer's origin.

show abstract

Section: Discussionmentioning

confidence: 94%

mentioning

confidence: 99%

Production of Enterocins L50A, L50B, and IT, a New Enterocin, by Enterococcus faecium IT62, a Strain Isolated from Italian Ryegrass in Japan

Izquierdo

Bednarczyk

Schaeffer

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…While heterogeneity in studies is found, one product, Enterococcus LAB SF68, had one end point, diarrhea lasting greater than 4 days, which was combinable and reported in the Cochrane review. Among the four studies with similar product and end point (84)(85)(86)(87), in the probiotic arms With respect to treatment of infectious diarrhea, it is theorized that by enhancing intestinal colonization by specifi c organisms there would be a reduction in the environmental niche for the off ending pathogen through production of acids, hydrogen peroxide, or other anti-microbial substances, increase of mucus production, and gut barrier defense, as well as competition for nutrients or adhesion receptors, antitoxin action, and stimulation of the immune system ( 82 ). In 2010, a Cochrane systematic review was published on the topic of probiotics and treatment of intestinal infection ( 83 ).…”

Section: Recommendationmentioning

confidence: 99%

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults

Riddle

DuPont

Connor

2016

American Journal of Gastroenterology

328

250

View full text Add to dashboard Cite

Acute diarrheal infections are a common health problem globally and among both individuals in the United States and traveling to developing world countries. Multiple modalities including antibiotic and non-antibiotic therapies have been used to address these common infections. Information on treatment, prevention, diagnostics, and the consequences of acute diarrhea infection has emerged and helps to inform clinical management. In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis, prevention, and treatment of acute diarrhea infection in both US-based and travel settings. Am J Gastroenterol 2016; 111:602-622; doi: 10.1038/ajg.2016 A follow-up survey where 3,568 respondents (median age 51) were asked at random about illness in the previous 7 days or previous month found that recall bias had an important eff ect on estimates of acute gastrointestinal illness ( 10 ). Using a 7-day exposure window, the estimated incidence of acute diarrhea was 1.6 episodes per person-year, compared with 0.9 episodes per person-year if asked about illness within the preceding month. Other population-based studies from Canada and western European countries using varied methodologies estimate annual incidence between 0.1 to 3.5 episodes per person-year ( 11 18. Antibiotic chemoprophylaxis has moderate to good effectiveness and may be considered in high-risk groups for short-term use. (Strong recommendation, high level of evidence) TD, traveler's diarrhea.

show abstract

“…faecium has already been used successfully in human for the treatment of acute diarrheal diseases and prevention of antibiotic-associated diarrhea (Wunderlich et al 1989;Buydens & Debeuckelaere 1996). The probiotic E. faecium HDRsEf1 strain which was separated by our research group has been licensed a China nation patent (Shi et al 2013) and already used as a feed additive for chicken and piglets; the feeding results demonstrate that HDRsEf1 can reduce diarrhea incidence and severity in weaning piglets and regulate the intestinal flora in chicken (Xiao et al 2014;Gong et al 2015), but the mechanism of intestine benefit remains unknown.…”

Section: Introductionmentioning

confidence: 99%

The inflammation regulation effects ofEnterococcus faeciumHDRsEf1 on human enterocyte-like HT-29 cells

Tian

Yang

et al. 2016

Animal Cells and Systems

View full text Add to dashboard Cite

Enterococcus faecium HDRsEf1 strain used as a probiotic to inhibit intestine inflammation and improve animal growth performance has been proved by our research team; however, it remains unclear how HDRsEf1 was recognized by intestine cells and how it activates the downstream pathway which benefit intestine health. In this study, HDRsEf1 was used to stimulate HT-29 cell line to partially uncover the intestine benefit mechanism of HDRsEf1. The results of cell viability assays showed that HDRsEf1 had no toxicity on HT-29 at concentrations up to 1 × 10 8 CFU/mL, HDRsEf1 could upregulate the TLR1, TLR2, and TLR6 mRNA level, especially TLR2, and significantly downregulate the mRNA level of TLR4, TLR5, TLR7, TLR8, but did not significantly affect the mRNA or protein level of MyD88, which suggests that HDRsEf1 activates the TLR2 pathway in an MyD88-independent pattern. HDRsEf1 could significantly downregulate the mRNA level of pro-inflammatory factors IL-1β, IL-6, IL-8, IL-12p35, IL-17, and TNF-α and did not affect the anti-inflammatory factors IL-10, PPAR-γ, and TSLP; besides HDRsEf1 did not upregulate the degradation of IκB in HT-29 cells. By contrast, enterohemorrhagic E. coli (EHEC) O157:H7 strongly up-regulated the mRNA level of pro-inflammatory factors IL-1β, IL-6, IL-8, IL-23, and TNF-α, downregulated obviously anti-inflammatory factor PPAR-ɣ, and obviously upregulated the degradation of IκB, which suggested that HDRsEf1 may act as an antagonist to regulate intestine inflammation response to intestine pathogen. These findings shed a light on the intestine benefit mechanism of HDRsEf1. ARTICLE HISTORY

show abstract

Efficacy of SF 68 in the Treatment of Acute Diarrhea a Placebo-Controlled Trial

Abstract: Oral bacteriotherapy with SF 68 strain shortens the duration and the severity of diarrhea in adults and represents a safe and effective approach to re-establishing a balanced microbial flora in this condition.

Cited by 76 publications

References 12 publications

Production of Enterocins L50A, L50B, and IT, a New Enterocin, by Enterococcus faecium IT62, a Strain Isolated from Italian Ryegrass in Japan

Production of Enterocins L50A, L50B, and IT, a New Enterocin, by Enterococcus faecium IT62, a Strain Isolated from Italian Ryegrass in Japan

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults

The inflammation regulation effects ofEnterococcus faeciumHDRsEf1 on human enterocyte-like HT-29 cells

Contact Info

Product

Resources

About